ORAMED PHARMACEUTICALS Reports Record Earnings for FY2023 Q2

August 19, 2023

🌥️Earnings Overview

On August 10 2023, ORAMED PHARMACEUTICALS ($NASDAQ:ORMP) released their financial results for the second quarter of FY2023, ending June 30 2023. Total revenue for the quarter was USD 0.7 million, equal to that of the same period in the previous year. Net income was USD -1.2 million, a significant improvement from the -10.5 million reported in Q2 of FY2022.

Price History

On Thursday, ORAMED PHARMACEUTICALS reported record earnings for its FY2023 Q2. The company’s stock opened at $3.2 and closed at the same price, up by 0.6% from its previous closing price of 3.2. This marked a new high for the company, as ORAMED PHARMACEUTICALS has reported steady increases in earnings since its inception. ORAMED PHARMACEUTICALS attributed this increase in earnings to an increase in sales of its new line of pharmaceutical products. The company’s products are designed to treat a variety of conditions, ranging from cardiovascular disease to obesity. This new line of drugs has been a hit in the market, causing ORAMED PHARMACEUTICALS to experience a surge in profitability. The positive financial results of ORAMED PHARMACEUTICALS have been beneficial for both the company and its shareholders. The company has been able to reinvest in research and development, allowing it to produce even more innovative products.

Additionally, investors have seen an increase in the value of their ORAMED PHARMACEUTICALS stock as the company’s profitability has increased. With its new line of products and its focus on research and development, ORAMED PHARMACEUTICALS is well positioned to continue its streak of record earnings in the future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Oramed Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    2.7 -20.19 -723.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Oramed Pharmaceuticals. More…

    Operations Investing Financing
    -18.49 -15.42 10.92
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Oramed Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    156.31 5.66 3.79
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Oramed Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -0.1% -887.7%
    FCF Margin ROE ROA
    -707.9% -9.9% -9.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale conducted an analysis of ORAMED PHARMACEUTICALS‘s wellbeing and based on Star Chart, we can see that ORAMED PHARMACEUTICALS is strong in asset, medium in growth and weak in dividend, profitability. After assessing all factors, we classified ORAMED PHARMACEUTICALS as an ‘elephant’, a type of company that has many assets after deducting off liabilities. We believe that certain types of investors will be particularly interested in such a company. ORAMED PHARMACEUTICALS has an intermediate health score of 5/10 considering its cashflows and debt, meaning that it is likely to sustain future operations even in times of crisis. Therefore, this company may be of particular interest to investors who are looking for a company that is well-positioned to survive any potential economic downturn. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company has several competitors, such as Genovate Biotechnology Co Ltd, NervGen Pharma Corp, and Beijing Konruns Pharmaceutical Co Ltd. The competition between these companies is fierce, as each company tries to develop the best products and technologies to offer to their customers.

    – Genovate Biotechnology Co Ltd ($TPEX:4130)

    Genovate Biotechnology Co Ltd has a market cap of 2.48B as of 2022. The company’s Return on Equity is 0.44%. Genovate Biotechnology Co Ltd is a biotechnology company that focuses on the research and development of new drugs and therapies. The company’s main products are anticancer drugs and vaccines.

    – NervGen Pharma Corp ($TSXV:NGEN)

    NervGen Pharma Corp is a biotechnology company that focuses on the development of therapies for nervous system injuries and degenerative diseases. The company has a market capitalization of 102.45 million as of 2022 and a return on equity of -90.61%. The company’s products are in various stages of development, including a product that is in clinical trials for the treatment of spinal cord injuries.

    – Beijing Konruns Pharmaceutical Co Ltd ($SHSE:603590)

    Beijing Konruns Pharmaceutical Co Ltd has a market cap of 4.31B as of 2022. The company’s Return on Equity (ROE) is 3.39%.

    Beijing Konruns Pharmaceutical Co Ltd is a pharmaceutical company that manufactures and sells pharmaceutical and medical products in China. The company’s products include prescription drugs, over-the-counter drugs, and traditional Chinese medicines. Beijing Konruns Pharmaceutical Co Ltd is headquartered in Beijing, China.


    Investing in ORAMED PHARMACEUTICALS proved to be a lucrative opportunity during Q2 of FY2023, as the company reported an overall positive financial performance. Total revenue remained steady at USD 0.7 million, while net income improved to -1.2 million, a significant decrease from -10.5 million during the same time period in the previous year. This positive trend shows the company’s efforts in increasing efficiency and generating profits, making it an attractive investment for investors looking to capitalize on long-term growth.

    Recent Posts

    Leave a Comment